Dr. Scott Gottlieb, nominated by Trump as FDA commissioner on March 10, beat out the more libertarian competitors Jim O’Neill and Balaji Srinivasan, both Silicon Valley insiders without a medical background.
An advocate of deregulation
Previous statements from Gottlieb suggest that he favors simplification of the approval pathway for generic drugs, in order to inject competition into the pharmaceutical market and ultimately reduce drug prices, which have risen rapidly.
Go deeper with GlobalData
Gottlieb favors lowering the quality of evidence and statistical rigor required to prove the effectiveness of a program for a successful new drug application, which would speed up the approval of novel drugs and encourage drug innovation.
In line with the flexibility shown by the FDA’s cancer division in recent years, initial drug approvals could hinge on relatively weak evidence, and doctors would be granted more decision-making power over which drugs they prescribe.
Criticism of Gottlieb’s plans
Opponents argue that the FDA review pathway is already the fastest in the developed world, and that solving the long-term decline in genuine innovation in the pharmaceutical industry is more complex than simply removing regulatory hurdles.
See Also:
Some critics say that doctors do not have the time or ability to provide regulatory oversight over the safest and most effective novel treatments for patients. They also point out that while the FDA has access to unpublished patient-level clinical trial data and the statistical expertise to correctly interpret it, physicians do not.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataReforms rather than regulatory rollbacks
The selection of Gottlieb is far more in line with existing FDA practices and policy directions than his competitors would have been, and his nomination will raise far less opposition from either side of the political aisle.
Related Company Profiles
Gottlieb LLC